Determination of cut-offs for circulating tumor cell measurement in metastatic cancer

Expert Review of Anticancer Therapy

Volumn 11, Issue 9, 2011, Pages 1345-1350

  Jacob, Jimmy ^a   Krell, Jonathan ^a   Castellano, Leandro ^a   Jiao, Long R ^a   Stebbing, Justin ^b   Frampton, Adam E ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

CirCe01; circulating tumor cells; IC 2006 04; metastatic breast cancer; overall survival; progression free survival; serum markers; SWOG 0500

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19; CYTOKERATIN 19 FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LACTATE DEHYDROGENASE; LAPATINIB; TAXANE DERIVATIVE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CELL ASSAY; CELL COUNT; CIRCULATING TUMOR CELL; CLINICAL EFFECTIVENESS; DISEASE FREE SURVIVAL; DISEASE MARKER; HUMAN; METASTASIS; OUTCOME ASSESSMENT; PROGNOSIS; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

EID: 80053014446     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.133     Document Type: Article

References (19)

1. Pierga JY, Hajage D, Bachelot T et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann. Oncol. DOI: 10.1093/annonc/mdr263 (2011) (Epub ahead of print).
2. Bidard FC, Hajage D, Bachelot T et al. Circulating tumor cells and CYFRA 21-1 As outcome-associated biomarkers in first line metastatic breast cancer: results of the IC 2006-04 Study. Ann. Oncol. 22(Suppl. 2), ii41-ii42 (2011).
3. Liu MC, Shields PG, Warren RD et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J. Clin. Oncol. 27(31), 5153-5159 (2009).
4. Nakamura S, Yagata H, Ohno S et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 17(3), 199-204 (2010).
5. Nole F, Munzone E, Zorzino L et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann. Oncol. 19(5), 891-897 (2008). (Pubitemid 351627303)
6. Giuliano M, Giordano A, Jackson S et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Research 13(3), R67 (2011).
7. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351(8), 781-791 (2004). (Pubitemid 39095313)
8. Nakata B, Ogawa Y, Ishikawa T et al. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer 89(6), 1285-1290 (2000).
9. Serrano MJ, Sanchez-Rovira P, Delgado- Rodriguez M, Gaforio JJ. Detection of circulating tumor cells in the context of treatment: prognostic value in breast cancer. Cancer Biol. Ther. 8(8), 671-675 (2009).
10. Bidard FC, Mathiot C, Degeorges A et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann. Oncol. 21(9), 1765-1771 (2010).
11. Rack B. Prognostic relevance of circulating tumor cells in the peripheral blood of primary breast cancer patients. SABCS (2010) (Abstract S6-S5).
12. Hayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J. Natl Cancer Inst. 88(20), 1456-1466 (1996). (Pubitemid 26340047)
13. Stott SL, Hsu CH, Tsukrov DI et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc. Natl Acad. Sci. USA 107(43), 18392-18397 (2010).
14. Danova M, Torchio M, Mazzini G. Isolation of rare circulating tumor cells in cancer patients: technical aspects and clinical implications. Expert Rev. Mol. Diagn. 11(5), 473-485 (2011).
15. Smirnov DA, Zweitzig DR, Foulk BW et al. Global Gene Expression Profiling of Circulating Tumor Cells. Cancer Res. 65(12), 4993-4997 (2005). (Pubitemid 40827303)
16. Flores LM, Kindelberger DW, Ligon AH et al. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br. J Cancer 102(10), 1495-1502 (2010).
17. Reyal F, Valet F, De Cremoux P et al. Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients. Ann. Oncol. 22(6), 1458-1459 (2011).
18. Sieuwerts AM, Mostert B, Bolt-De Vries J et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin. Cancer Res. 17(11), 3600-3618 (2011).
19. Gao H. Detection of circulating tumor cells prior to autologous stem cell transplantation is predictive of shorter progression free survival in metastatic breast cancer. SABCS (2010) (Abstract P3-02-08).